Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23356575 | 0.86 | POLB (0.37) | POLBKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL29657255 | 0.81 | TDP1 (0.34) | LMNAKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL29657243 | 0.78 | ALDH1A1 (0.43) | LMNAKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL27621944 | 0.77 | POLB (0.38) | POLBKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL23356557 | 0.69 | TDP1 (0.36) | POLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL27742275 | 0.67 | LMNA (0.37) | LMNAHTTKMT2AMEN1ALDH1A1 | |
| SCHEMBL29657125 | 0.65 | CYP1A2 (0.38) | LMNAHTTKMT2AMEN1ALDH1A1 | |
| SCHEMBL5141131 | 0.62 | TDP1 (0.40) | HTTPOLBKMT2AMEN1MAPK1 | |
| SCHEMBL29657189 | 0.62 | TDP1 (0.34) | LMNAKMT2AALDH1A1 | |
| SCHEMBL23356587 | 0.62 | MAPT (0.43) | KMT2AMEN1MAPK1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-03-29 | — | — | US | claimed |
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | CBR1, POR, CAT | LMNA 1721/4885HTT 4255/4885POLB 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.